Literature DB >> 8723684

Phenotypic expression in double heterozygotes for familial hypercholesterolemia and familial defective apolipoprotein B-100.

P Benlian1, J L de Gennes, F Dairou, B Hermelin, I Ginon, E Villain, J P Lagarde, M C Federspiel, V Bertrand, C Bernard, G Bereziat.   

Abstract

Variability in the expression of monogenic lipid disorders may be observed in patients carrying the same DNA mutation, suggesting possible genetic or environmental interactions. Our objective was to investigate the genotype-phenotype relationships in two unrelated French patients with an aggravated expression of a dominantly inherited hypercholesterolemia. In probands, segregation analysis complemented by DNA sequencing identified heterozygous defective alleles and mutations on two nonallelic loci for two monogenic lipid disorders: familial hypercholesterolemia at the low density lipoprotein (LDL) receptor locus and familial defective apolipoprotein B-100 at the locus encoding its ligand, apolipoprotein B-100. The LDL-receptor missense mutations had been reported in French Canadians. The apolipoprotein B mutation was the Arg3500Gln founder mutation in Northern Europe. Probands had an unusual phenotype of aggravated hypercholesterolemia that was complicated with premature coronary arterial disease, although remaining responsive to lipid-lowering drugs. This phenotype was distinct from that observed in their heterozygous relatives and distinct from those observed in FH or FDB homozygotes. These cases refer to a new class of patients with digenic lipid disorders, defined by specific clinical features that result from the combined effects of two independent loci. Moreover, the observed phenotype of aggravated hypercholesterolemia gives further evidence that receptor and ligand play distinct roles in regulating LDL metabolism. Although uncommon, these cases give insight into the molecular mechanisms that underly the clinical variability of inherited hypercholesterolemia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8723684     DOI: 10.1002/(SICI)1098-1004(1996)7:4<340::AID-HUMU8>3.0.CO;2-C

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  6 in total

Review 1.  Statins in homozygous familial hypercholesterolemia.

Authors:  A D Marais; D J Blom; J C Firth
Journal:  Curr Atheroscler Rep       Date:  2002-01       Impact factor: 5.113

Review 2.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

Review 3.  Genetics of familial hypercholesterolemia.

Authors:  Ariel Brautbar; Emili Leary; Kristen Rasmussen; Don P Wilson; Robert D Steiner; Salim Virani
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

Review 4.  Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk.

Authors:  Sebastiano Calandra; Patrizia Tarugi; Helen E Speedy; Andrew F Dean; Stefano Bertolini; Carol C Shoulders
Journal:  J Lipid Res       Date:  2011-08-23       Impact factor: 5.922

5.  Pairwise effects between lipid GWAS genes modulate lipid plasma levels and cellular uptake.

Authors:  Magdalena Zimoń; Yunfeng Huang; Anthi Trasta; Aliaksandr Halavatyi; Jimmy Z Liu; Chia-Yen Chen; Peter Blattmann; Bernd Klaus; Christopher D Whelan; David Sexton; Sally John; Wolfgang Huber; Ellen A Tsai; Rainer Pepperkok; Heiko Runz
Journal:  Nat Commun       Date:  2021-11-05       Impact factor: 14.919

6.  New Sequencing technologies help revealing unexpected mutations in Autosomal Dominant Hypercholesterolemia.

Authors:  Sandy Elbitar; Delia Susan-Resiga; Youmna Ghaleb; Petra El Khoury; Gina Peloso; Nathan Stitziel; Jean-Pierre Rabès; Valérie Carreau; Josée Hamelin; Ali Ben-Djoudi-Ouadda; Eric Bruckert; Catherine Boileau; Nabil G Seidah; Mathilde Varret; Marianne Abifadel
Journal:  Sci Rep       Date:  2018-01-31       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.